Luciole is a start-up biotechnology company discovering and developing small molecule activators of OGG1, to accelerate the repair of oxidative damage to mitochondrial DNA. Luciole Pharmaceuticals is developing first-in-class agents as disease-modifying therapeutics for diseases of aging. Our efforts have the potential to lead to the discovery of a novel, safe, and very effective oral medicine for obesity and metabolic syndrome, fatty liver disease and neurodegeneration, which will improve patients’ quality-of-life and increase their life expectancy.